H.R. 7091: Expanding Veterans’ Access to Emerging Treatments Act

This bill, known as the "Expanding Veterans’ Access to Emerging Treatments Act," aims to enhance the access of U.S. military veterans to innovative treatments and therapies for specific medical conditions that currently have limited treatment options. The key objectives and processes outlined in the bill include:

Establishment of a Research Program

The bill mandates that within 90 days of its enactment, the Secretary of Veterans Affairs must create a research program focusing on innovative treatments for veterans diagnosed with certain medical conditions. Additionally, within 60 days, the Secretary must appoint a lead administrator to oversee the program.

Clinical Trials and Access

The Department of Veterans Affairs (VA) is authorized to conduct clinical trials that involve veterans using new and innovative treatments. The program will focus on:

• Evaluating the effectiveness, safety, and administration of various innovative treatments.
• Establishing protocols for compassionate or extended access to these innovative therapies when deemed clinically appropriate.

Conditions Covered

The bill identifies specific health conditions for which veterans might seek these treatments. These "covered conditions" include:

• Anxiety
• Chronic pain
• Depression
• Post-traumatic stress disorder (PTSD)
• Substance use disorders
• Traumatic brain injury

Research Funding and Reporting

The Secretary is permitted to allocate funds for conducting clinical trials on innovative treatments. The bill also calls for a report to be submitted to Congress within a year after enactment, covering:

• Details of clinics involved in the research, including participation numbers.
• Initial findings and outcomes from the clinical trials.
• A comprehensive review of all treatments used for covered conditions, including their safety and efficacy.

Definitions and Scope

The bill defines key terms such as:

• Innovative treatments: This includes substances like psychedelics and other emerging therapies, such as 3,4-Methylenedioxy-methamphetamine (MDMA), ketamine, psilocybin, and ibogaine.
• Emerging therapies: Refers to investigational drugs and medical devices, potentially including new pharmaceutical candidates and innovative interventions.

Program Review

The investigational program will undergo a review by the Secretary two years after the enactment of the bill, allowing for either extension or termination based on its performance and outcomes.

Compliance with Existing Laws

The bill clarifies that its provisions must be consistent with existing federal laws governing investigational medical products and controlled substances.

Relevant Companies

• AGIO - A biopharmaceutical company that may develop treatments relevant to the conditions outlined in the bill.
• COMP - A company focused on emerging therapies potentially applicable to veteran health issues addressed in the bill.
• PYXL - A biotech firm that may be involved in research and development of innovative treatments named in the bill.